Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 7/20 | 0.62 |
| ▸ | KIF11 | P52732 | 4/20 | 0.47 |
| ▸ | RORC | P51449 | 5/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | ACSS2 | Q9NR19 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2390681 | 1.00 | CYP19A1 (0.62) | CYP19A1KIF11RORCTSHRMAPK1 | |
| SCHEMBL30791490 | 1.00 | CYP19A1 (0.62) | CYP19A1KIF11RORCTSHRMAPK1 | |
| SCHEMBL8860094 | 0.93 | CYP19A1 (0.69) | CYP19A1KIF11RORCTSHRMAPK1 | |
| SCHEMBL22319803 | 0.82 | SMN1; SMN2 (0.56) | CYP19A1KIF11RORCL3MBTL1 | |
| SCHEMBL24158366 | 0.81 | CYP19A1 (0.46) | CYP19A1KIF11RORCTSHRL3MBTL1 | |
| SCHEMBL10841821 | 0.80 | CYP19A1 (0.55) | CYP19A1KIF11TSHRMAPK1NPSR1 | |
| SCHEMBL11300726 | 0.79 | CYP19A1 (0.53) | CYP19A1KIF11TSHRMAPK1NPSR1 | |
| SCHEMBL2389063 | 0.79 | CYP19A1 (0.62) | CYP19A1TSHRMAPK1 | |
| SCHEMBL2391264 | 0.79 | CYP19A1 (0.62) | CYP19A1TSHRMAPK1 | |
| SCHEMBL5591840 | 0.79 | SIGMAR1 (0.54) | CYP19A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117630242-A | Method for separating and detecting impurity a in clotrimazole intermediate by high performance liquid chromatography | 重庆华邦制药有限公司 | 2024-03-01 | — | — | CN | disclosed |
| US-8026263-B2 | Methods for inhibiting neoproliferative changes in blood vessel walls | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-09-27 | — | — | US | disclosed |
| US-8026263-B2 | Methods for inhibiting neoproliferative changes in blood vessel walls | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-09-27 | — | — | US | disclosed |
| US-8026263-B2 | Methods for inhibiting neoproliferative changes in blood vessel walls | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-09-27 | — | — | US | disclosed |
| US-20090048270-A1 | Compounds, Methods And Devices for Inhibiting Neoproliferative Changes in Blood Vessel Walls | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-02-19 | — | — | US | disclosed |
| US-20070293554-A1 | Non-peptide inhibition of T-lymphocyte activation and therapies related thereto | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2007-12-20 | — | — | US | disclosed |
| US-7235577-B1 | Non-peptide inhibition of T-lymphocyte activation and therapies related thereto | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-06-26 | — | — | US | disclosed |
| US-7235577-B1 | Non-peptide inhibition of T-lymphocyte activation and therapies related thereto | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-06-26 | — | — | US | disclosed |
| US-7235577-B1 | Non-peptide inhibition of T-lymphocyte activation and therapies related thereto | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-06-26 | — | — | US | disclosed |
| US-6803375-B1 | IMMUNOMODULATION IN A MAMMALIAN PATIENT WITHOUT CAUSING SUBSTANTIAL INHIBITION OF CYTOCHROME P-450 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2004-10-12 | — | — | US | disclosed |
| EP-0703498-B1 | Photosensitive resin composition and method for forming a photoresist pattern | MITSUBISHI CHEM CORP (JP) | 1997-12-29 | — | — | EP | disclosed |
| US-5698362-A | CONTAINING A TRIARYLMETHANE DERIVATIVE; HIGH RESOLUTION, EXCELLENT IN DEPTH OF FOCUS AND PATTERN PROFILE, STORAGE STABLE | MITSUBISHI CHEMICAL CORPORATION (JP) | 1997-12-16 | — | — | US | disclosed |
| EP-0703498-A1 | Photosensitive resin composition and method for forming a photoresist pattern | MITSUBISHI CHEMICAL CORPORATION (JP) | 1996-03-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048270-A1 | Compounds, Methods And Devices for Inhibiting Neoproliferative Changes in Blood Vessel Walls | PGF, VEGFA, MKI67 | CYP19A1 685/4885KIF11 2931/4885RORC 3064/4885 |
| US-20070293554-A1 | Non-peptide inhibition of T-lymphocyte activation and therapies related thereto | NFATC1, ORAI1, KCNMA1 | CYP19A1 424/4885KIF11 4687/4885RORC 992/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.